Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.5402
-0.0703 (-11.52%)
At close: Jun 18, 2026, 4:00 PM EDT
0.6100
+0.0698 (12.92%)
After-hours: Jun 18, 2026, 5:47 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $20.00K in the quarter ending February 28, 2026, a decrease of -88.51%. This brings the company's revenue in the last twelve months to $368.00K, down -30.03% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth.
Revenue (ttm)
$368.00K
Revenue Growth
-30.03%
P/S Ratio
43.97
Revenue / Employee
$52,571
Employees
7
Market Cap
13.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | 222.61K | -210.68K | -48.62% |
| Aug 31, 2018 | 433.29K | 369.65K | 580.85% |
| Aug 31, 2017 | 63.64K | 22.92K | 56.29% |
| Aug 31, 2016 | 40.72K | 26.02K | 176.96% |
| Aug 31, 2015 | 14.70K | - | - |
| Aug 31, 2014 | - | - | - |
| Oct 31, 2013 | 1.10M | -260.30K | -19.17% |
| Oct 31, 2012 | 1.36M | 223.99K | 19.76% |
| Oct 31, 2011 | 1.13M | 771.30K | 212.79% |
| Oct 31, 2010 | 362.47K | -59.48K | -14.10% |
| Oct 31, 2009 | 421.96K | -478.83K | -53.16% |
| Oct 31, 2008 | 900.79K | 647.64K | 255.83% |
| Oct 31, 2007 | 253.15K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLEXX News
- 1 day ago - Lexaria Bioscience provides update on GLP-1 oral pill market - TheFly
- 1 day ago - GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand - Accesswire
- 1 day ago - GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand - TheNewswire
- 9 days ago - Lexaria announces dosing completion in 2026 Animal Study 2 - TheFly
- 9 days ago - Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway. - TheNewswire
- 9 days ago - Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway - Accesswire
- 15 days ago - Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program - TheNewswire
- 15 days ago - Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program - Accesswire